Meritage Portfolio Management Atea Pharmaceuticals, Inc. Transaction History

Meritage Portfolio Management

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 25, 2023	SELL	$3.0 - $4.97 $2,214 - $3,667	-738 Reduced 3.32%	21,476 $72,000
Q4 2022 Feb 01, 2023	BUY	$4.35 - $6.17 $3,388 - $4,806	779 Added 3.63%	22,214 $107,000
Q3 2022 Oct 25, 2022	BUY	$5.49 - $8.79 $417 - $668	76 Added 0.36%	21,435 $122,000
Q2 2022 Jul 25, 2022	BUY	$5.33 - $8.18 $3,150 - $4,834	591 Added 2.85%	21,359 $152,000
Q1 2022 Apr 25, 2022	BUY	$5.5 - $9.19 $14,492 - $24,215	2,635 Added 14.53%	20,768 $150,000
Q4 2021 Jan 28, 2022	BUY	$7.67 - $44.59 $139,080 - $808,550	18,133 New	18,133 $162,000

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $275M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Meritage Portfolio Management, based on Form 13F filings with the SEC.

Stay updated on Meritage Portfolio Management with notifications on news.